PHMB Stock Overview
PharmaCom BioVet, Inc. focuses on operating a network of companion animal cancer treatment centers in the United States.
| Snowflake Score | |
|---|---|
| Valuation | 0/6 |
| Future Growth | 0/6 |
| Past Performance | 0/6 |
| Financial Health | 0/6 |
| Dividends | 0/6 |
PharmaCom BioVet, Inc. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$0.000001 |
| 52 Week High | US$0.000001 |
| 52 Week Low | US$0.000001 |
| Beta | 0 |
| 1 Month Change | 0% |
| 3 Month Change | 0% |
| 1 Year Change | n/a |
| 3 Year Change | -99.67% |
| 5 Year Change | -99.00% |
| Change since IPO | -100.00% |
Recent News & Updates
No updates
Recent updates
No updates
Shareholder Returns
| PHMB | US Healthcare | US Market | |
|---|---|---|---|
| 7D | 0% | 0.6% | 1.0% |
| 1Y | n/a | 2.2% | 21.9% |
Return vs Industry: Insufficient data to determine how PHMB performed against the US Healthcare industry.
Return vs Market: Insufficient data to determine how PHMB performed against the US Market.
Price Volatility
| PHMB volatility | |
|---|---|
| PHMB Average Weekly Movement | n/a |
| Healthcare Industry Average Movement | 7.3% |
| Market Average Movement | 6.0% |
| 10% most volatile stocks in US Market | 16.8% |
| 10% least volatile stocks in US Market | 3.0% |
Stable Share Price: PHMB has not had significant price volatility in the past 3 months.
Volatility Over Time: Insufficient data to determine PHMB's volatility change over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 1995 | n/a | n/a | n/a |
PharmaCom BioVet, Inc. focuses on operating a network of companion animal cancer treatment centers in the United States. The company focuses on developing bone marrow transplantation and other cancer treatment procedures to benefit companion animals that are diagnosed with lymphoma, other different types of cancers, and other diseases that are incurable. It has licensed a series of proprietary devices and compounds that would reduce suffering in animals with cancer.
PharmaCom BioVet, Inc. Fundamentals Summary
| PHMB fundamental statistics | |
|---|---|
| Market cap | US$10.78k |
| Earnings (TTM) | US$0 |
| Revenue (TTM) | n/a |
n/a
P/E Ration/a
P/S RatioIs PHMB overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| PHMB income statement (TTM) | |
|---|---|
| Revenue | US$0 |
| Cost of Revenue | US$0 |
| Gross Profit | US$0 |
| Other Expenses | US$0 |
| Earnings | US$0 |
Last Reported Earnings
n/a
Next Earnings Date
n/a
| Earnings per share (EPS) | 0 |
| Gross Margin | 0.00% |
| Net Profit Margin | 0.00% |
| Debt/Equity Ratio | 0.0% |
How did PHMB perform over the long term?
See historical performance and comparison